AYTU - Aytu BioScience, Inc.
| Previous Close | 1.8500 |
| Open | 1.8400 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 1200 |
| Day's Range | 1.8100 - 1.8800 |
| 52 Week Range | 0.6800 - 7.8000 |
| Volume | 60,817 |
| Avg. Volume | 366,564 |
| Market Cap | 30.155M |
| Beta (3Y Monthly) | 4.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5020 |
| Earnings Date | Feb 7, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- ACCESSWIRE•yesterday
MiOXSYS(R) Male Infertility Test Will be Featured in Product Theatre Symposium at 35th Annual Meeting of the European Society of Human Reproduction and Embryology
ENGLEWOOD, CO / ACCESSWIRE / June 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced ...
- ACCESSWIRE•7 days ago
Aytu BioScience Announces Presentation of Novel Clinical Findings for its Proprietary MiOXSYS(R) Male Infertility Test at Global Reproductive Medicine Scientific Conference
11 Abstracts Featuring MiOXSYS have been Selected for Presentation at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology ENGLEWOOD, CO / ACCESSWIRE / June 18, 2019 / Aytu ...
- ACCESSWIRE•13 days ago
Aytu BioScience Featured in Local NBC News Segment (VIDEO): ''Nasal Spray for Low Testosterone Preserves Fertility''
Low testosterone affects more than 10% of men worldwide. Dr. Ranjith Ramasamy, Director of Reproductive Urology at the University of Miami Health System, said, 'At least one in three men between the ages of 32 to 50 appear to have low testosterone.' Ramasamy said factors such as stress, obesity, and poor sleep habits may be to blame. Symptoms include 'low energy, fatigue, improper sleep, weight gain, erectile dysfunction or lack of libido,' Ramasamy explained.
- ACCESSWIRE•14 days ago
Aytu BioScience Set to Join Russell Microcap (R) Index
ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual reconstitution. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "Inclusion in the Russell Microcap Index underscores the progress we are making to increase shareholder value through our continued growth and the expansion of our product portfolio," said Josh Disbrow, Aytu BioScience's Chief Executive Officer.
- Zacks•20 days ago
Myriad Genetics Announces Study Results Of myRisk Cancer Test
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
- ACCESSWIRE•21 days ago
Aytu BioScience Announces Exclusive Distribution Agreement with Beijing Dahua Sanxin Technology Development Co., Ltd. to Commercialize MiOXSYS(R) Male Infertility Test in China
Initial Purchase by Beijing Dahua Sanxin Technology Development Co., Ltd. Represents First MiOXSYS Commercial Sale in China. ENGLEWOOD, CO / ACCESSWIRE / June 4, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), ...
- Zacks•26 days ago
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
Is (AYTU) Outperforming Other Medical Stocks This Year?
- ACCESSWIRE•last month
Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United Kingdom
ENGLEWOOD, CO / ACCESSWIRE / May 21, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that MiOXSYS®, the company's first-in-class seminal oxidative stress test for the assessment of male infertility, is now available in the United Kingdom. MiOXSYS, the Male Infertility Oxidative System, is CE marked and cleared by Health Canada, Australia's TGA, and Mexico's COFEPRIS. MiOXSYS is the first cleared advanced in vitro diagnostic test that assesses seminal oxidative stress, a major cause of male infertility.
- Zacks•last month
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy
Aytu Bioscience, Inc. (AYTU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- ACCESSWIRE•last month
Aytu BioScience Reports 291% Revenue Growth in Q3 FY19
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products ...
- ACCESSWIRE•2 months ago
Aytu BioScience to Report Fiscal Third Quarter 2019 Results and Business Update
Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / ACCESSWIRE / May 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused ...
- ACCESSWIRE•2 months ago
Aytu BioScience Announces Submission of ZolpiMist (TM) for Approval to Australian Therapeutic Goods Administration (TGA)
Australian TGA Approval Decision Expected in Early 2020 ENGLEWOOD, CO / ACCESSWIRE / April 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization ...
- ACCESSWIRE•2 months ago
Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors
ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the formal appointment of Steven Boyd, Founder and Chief Investment Officer of Armistice Capital, to the Aytu BioScience board of directors. As previously announced in December 2018, the company planned to formally appoint Mr. Boyd at an upcoming board of directors meeting in early 2019.
- Zacks•2 months ago
Aytu Bioscience, Inc. (AYTU) Moves to Buy: Rationale Behind the Upgrade
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- ACCESSWIRE•3 months ago
Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment
ENGLEWOOD, CO / ACCESSWIRE / March 27, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is providing an enrollment update for the ongoing Natesto Spermatogenesis Study, the Phase 4 clinical trial investigating the impact of nasally-administered Natesto on preservation of fertility parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator.
- ACCESSWIRE•3 months ago
Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels
ENGLEWOOD, CO / ACCESSWIRE / March 19, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, announced two recent publications summarizing findings from the Phase 4, Natesto® ''MY-T study.'' The MY-T study is the first clinical trial documenting that patients' hypogonadal symptoms improved after switching to Natesto from a topical testosterone gel. Further, the results confirmed the majority of patients prefer Natesto over topical testosterone gels and had higher levels of treatment satisfaction.
- ACCESSWIRE•3 months ago
Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences
Datato be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating theEffect of Natesto Nasal Testosterone on Male Fertility Parameters ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Aytu BioScience, ...
- Zacks•3 months ago
Aytu Bioscience, Inc. (AYTU) Upgraded to Buy: What Does It Mean for the Stock?
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Simply Wall St.•4 months ago
What Percentage Of Aytu BioScience, Inc. (NASDAQ:AYTU) Shares Do Insiders Own?
A look at the shareholders of Aytu BioScience, Inc. (NASDAQ:AYTU) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...
- ACCESSWIRE•4 months ago
Aytu BioScience Announces ZolpiMist (TM) Global Distribution Agreement with SUDA Pharmaceuticals
Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada ENGLEWOOD, CO / ACCESSWIRE / March 6, 2019 / Aytu BioScience, ...
- ACCESSWIRE•4 months ago
Aytu BioScience Announces ZolpiMist(TM) Global Distribution Agreement with SUDA Pharmaceuticals
Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada ENGLEWOOD, CO / ACCESSWIRE / March 6, 2019 / Aytu BioScience, ...
- ACCESSWIRE•5 months ago
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19
Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / February 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products ...
- ACCESSWIRE•5 months ago
Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update
Live Conference Call and Webcast Scheduled for February 7, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / ACCESSWIRE / January 31, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...
- ACCESSWIRE•5 months ago
Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR
Tuzistra XR Enters the $3 Billion Cough and Cold Market, with 30-35 Million Prescriptions Written Annually Nationwide Field Promotion Begins for Tuzistra XR, Only 12-Hour Codeine-Based Antitussive, 2-3 ...
- ACCESSWIRE•5 months ago
Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program
Natesto Total Prescriptions Increased 27% and Refill Prescriptions Increased 52% Sequentially ENGLEWOOD, CO / ACCESSWIRE / January 10, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical ...
